Navco Pharmaceuticals Inc.
NAV.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 95.00% | 95.50% | -280.45% | 60.12% | 37.75% |
| Total Depreciation and Amortization | -97.09% | -95.97% | -144.98% | -105.17% | -47.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -98.88% | -98.95% | 144.79% | -67.54% | -6.16% |
| Change in Net Operating Assets | -90.75% | -91.47% | -72.84% | 172.69% | 167.42% |
| Cash from Operations | 79.02% | 91.74% | 93.73% | 97.25% | 94.70% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -51.86% | -51.86% | 162.03% | -- | -- |
| Total Debt Repaid | 100.00% | 74.75% | 53.92% | 72.71% | 60.76% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -23.12% | -38.42% | 224.66% | -89.18% | -98.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.27% | 97.79% | 99.28% | 99.81% | -246.82% |